FR04C0028I2 - - Google Patents
Info
- Publication number
- FR04C0028I2 FR04C0028I2 FR04C0028C FR04C0028C FR04C0028I2 FR 04C0028 I2 FR04C0028 I2 FR 04C0028I2 FR 04C0028 C FR04C0028 C FR 04C0028C FR 04C0028 C FR04C0028 C FR 04C0028C FR 04C0028 I2 FR04C0028 I2 FR 04C0028I2
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75720596A | 1996-11-27 | 1996-11-27 | |
| PCT/US1997/019041 WO1998023761A1 (en) | 1996-11-27 | 1997-10-20 | HUMANIZED ANTI-CD11a ANTIBODIES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR04C0028I1 FR04C0028I1 (instruction) | 2005-02-11 |
| FR04C0028I2 true FR04C0028I2 (instruction) | 2007-10-26 |
Family
ID=25046834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR04C0028C Active FR04C0028I2 (instruction) | 1996-11-27 | 2004-12-10 |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP1516629B1 (instruction) |
| JP (2) | JP3778945B2 (instruction) |
| KR (1) | KR100532178B1 (instruction) |
| AR (1) | AR008919A1 (instruction) |
| AT (1) | ATE267257T1 (instruction) |
| AU (1) | AU731817C (instruction) |
| CA (1) | CA2272842C (instruction) |
| DE (3) | DE69729209T2 (instruction) |
| DK (2) | DK0941344T3 (instruction) |
| ES (1) | ES2221045T3 (instruction) |
| FR (1) | FR04C0028I2 (instruction) |
| IL (3) | IL130143A0 (instruction) |
| LU (1) | LU91122I2 (instruction) |
| NL (1) | NL300163I2 (instruction) |
| PT (1) | PT941344E (instruction) |
| WO (1) | WO1998023761A1 (instruction) |
| ZA (1) | ZA979599B (instruction) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| SI1135498T1 (sl) | 1998-11-18 | 2008-06-30 | Genentech Inc | Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi |
| EP1163003B1 (en) | 1999-03-19 | 2009-08-12 | Genentech, Inc. | Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist |
| US6582698B1 (en) | 1999-03-19 | 2003-06-24 | Genentech, Inc. | Treatment method |
| EP1237575B1 (en) * | 1999-12-14 | 2008-08-06 | Genentech, Inc. | Tnf-alpha antagonist and lfa-1 antagonist for treating rheumatoid arthritis |
| US7575921B2 (en) | 1999-12-30 | 2009-08-18 | Vbi Technologies, L.L.C. | Spore-like cells and uses thereof |
| US7560275B2 (en) | 1999-12-30 | 2009-07-14 | Vbi Technologies, L.L.C. | Compositions and methods for generating skin |
| AU2001230920A1 (en) * | 2000-01-14 | 2001-07-24 | Genentech Inc. | Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1 |
| EP1315812B1 (en) * | 2000-09-01 | 2009-11-11 | The Center for Blood Research, INC. | Modified polypeptides stabilized in a desired conformation and methods for producing same |
| US20020151050A1 (en) | 2000-10-30 | 2002-10-17 | Vacanti Charles A. | Isolation of spore-like cells from tissues exposed to extreme conditions |
| CA2473144C (en) | 2002-02-05 | 2013-05-28 | Genentech, Inc. | Protein purification |
| WO2003102132A2 (en) | 2002-04-26 | 2003-12-11 | Genetech, Inc. | Non-affinity purification of proteins |
| ATE493433T1 (de) | 2002-09-11 | 2011-01-15 | Genentech Inc | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen |
| US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| BRPI0410492A (pt) * | 2003-04-23 | 2006-06-13 | Medarex Inc | anticorpos humanizado, método para inibir a ligação de interferon-i a receptor-1, para inibição de uma resposta imune, para tratar uma desordem autoimune, para modificar nìveis de crp do soro, para nìveis de neopterina do soro e para modificar a proliferação de células-b, e anticorpo quimérico |
| SI3095793T1 (sl) | 2003-07-28 | 2020-07-31 | Genentech, Inc. | Zmanjšanje izluževanja proteina A med afinitetno kromatografijo proteina A |
| EP1716181B1 (en) | 2004-02-19 | 2009-12-16 | Genentech, Inc. | Cdr-repaired antibodies |
| EP1761562B1 (en) * | 2004-02-19 | 2013-09-11 | Dyax Corp. | Conformation specific antibodies |
| BRPI0511305A (pt) | 2004-06-09 | 2007-12-04 | Genentech Inc | método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1 |
| US7662926B2 (en) | 2004-09-02 | 2010-02-16 | Genentech, Inc. | Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor |
| US7655229B2 (en) | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| FR2902799B1 (fr) | 2006-06-27 | 2012-10-26 | Millipore Corp | Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide |
| WO2008079302A2 (en) | 2006-12-21 | 2008-07-03 | Millipore Corporation | Purification of proteins |
| US8569464B2 (en) | 2006-12-21 | 2013-10-29 | Emd Millipore Corporation | Purification of proteins |
| US8362217B2 (en) | 2006-12-21 | 2013-01-29 | Emd Millipore Corporation | Purification of proteins |
| US7947813B2 (en) | 2007-01-22 | 2011-05-24 | Genentech, Inc. | Polyelectrolyte precipitation and purification of proteins |
| SI2188302T1 (en) | 2007-07-09 | 2018-07-31 | Genentech, Inc. | Prevention of the reduction of the disulfide bond during the recombinant production of polypeptides |
| TWI554517B (zh) | 2007-10-30 | 2016-10-21 | 建南德克公司 | 藉陽離子交換層析法純化抗體 |
| CN110082533B (zh) * | 2008-04-09 | 2023-01-10 | 健泰科生物技术公司 | 用于免疫相关疾病的治疗的新组合物和方法 |
| US8999702B2 (en) | 2008-06-11 | 2015-04-07 | Emd Millipore Corporation | Stirred tank bioreactor |
| EP2145901B1 (en) | 2008-07-18 | 2012-11-14 | Technische Universität Braunschweig | Recombinant anti-MUC1 antibodies |
| EP2321337B2 (en) | 2008-08-14 | 2018-10-10 | Genentech, Inc. | Methods for removing a contaminant using protein displacement ion exchange membrane chromatography |
| KR20110076918A (ko) | 2008-09-10 | 2011-07-06 | 제넨테크, 인크. | 단백질의 산화성 분해를 방지하기 위한 조성물 및 방법 |
| WO2010074953A1 (en) | 2008-12-16 | 2010-07-01 | Millipore Corporation | Stirred tank reactor and method |
| US20110020327A1 (en) | 2008-12-16 | 2011-01-27 | Millipore Corporation | Purification of proteins |
| WO2010099273A1 (en) | 2009-02-27 | 2010-09-02 | Genentech, Inc. | Methods and compositions for protein labelling |
| FI2464725T4 (fi) | 2009-08-11 | 2025-03-21 | Hoffmann La Roche | Proteiinien tuotanto glutamiinittomassa soluviljelyn elatusaineessa |
| PL2473617T3 (pl) | 2009-09-01 | 2020-06-29 | F. Hoffmann-La Roche Ag | Ulepszone oczyszczanie białka poprzez zmodyfikowaną elucję z białka A |
| IN2012DN05181A (instruction) | 2009-11-12 | 2015-10-23 | Vbi Technologies Llc | |
| EP2531592A1 (en) | 2010-02-04 | 2012-12-12 | Vivalis | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
| PL2550018T3 (pl) | 2010-03-22 | 2019-08-30 | F.Hoffmann-La Roche Ag | Kompozycje i sposoby użyteczne do stabilizowania preparatów zawierających białko |
| CN102958538A (zh) | 2010-05-03 | 2013-03-06 | 弗·哈夫曼-拉罗切有限公司 | 用于降低含有蛋白质的制剂的粘度的组合物和方法 |
| US8691918B2 (en) | 2010-05-17 | 2014-04-08 | Emd Millipore Corporation | Stimulus responsive polymers for the purification of biomolecules |
| KR20190067277A (ko) | 2010-05-28 | 2019-06-14 | 제넨테크, 인크. | 락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가 |
| CA2802756C (en) | 2010-06-24 | 2021-05-04 | Genentech, Inc. | Compositions and methods for stabilizing protein-containing formulations |
| MX2013001267A (es) | 2010-08-13 | 2013-04-10 | Genentech Inc | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. |
| WO2012030512A1 (en) | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
| US9814740B2 (en) * | 2010-12-21 | 2017-11-14 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
| WO2012095514A1 (en) | 2011-01-14 | 2012-07-19 | Vivalis | Recombinant protein production system |
| SG11201403437TA (en) | 2011-12-22 | 2014-07-30 | Genentech Inc | Ion exchange membrane chromatography |
| SG10201912877SA (en) | 2012-03-27 | 2020-02-27 | Genentech Inc | Improved harvest operations for recombinant proteins |
| HUE071647T2 (hu) | 2012-05-18 | 2025-09-28 | Genentech Inc | Magas koncentrációjú monoklonális antitest készítmények |
| US9393327B2 (en) | 2012-12-19 | 2016-07-19 | Genentech, Inc. | Methods and compositions for radiohalogen protein labeling |
| NZ715455A (en) | 2013-07-09 | 2021-12-24 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
| HRP20201404T1 (hr) | 2013-07-16 | 2020-11-27 | F. Hoffmann - La Roche Ag | Postupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita |
| PL3166401T3 (pl) | 2014-07-09 | 2021-01-25 | F. Hoffmann-La Roche Ag | Dostosowanie pH w celu poprawy wyników regeneracji banków komórek po rozmrożeniu |
| WO2016073685A1 (en) | 2014-11-05 | 2016-05-12 | Annexon, Inc. | Humanized anti-complement factor c1q antibodies and uses thereof |
| CN108137691B (zh) | 2015-09-02 | 2021-10-19 | 耶路撒冷希伯来大学伊萨姆研究发展有限公司 | 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体 |
| TWI811892B (zh) | 2015-09-25 | 2023-08-11 | 美商建南德克公司 | 抗tigit抗體及使用方法 |
| WO2017091719A1 (en) | 2015-11-24 | 2017-06-01 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| EP3436610A1 (en) | 2016-03-29 | 2019-02-06 | Geltor, Inc. | Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1 |
| AU2017382281B2 (en) | 2016-12-22 | 2024-07-11 | Genentech, Inc. | Methods and formulations for reducing reconstitution time of lyophilized polypeptides |
| US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
| JP7419273B2 (ja) | 2018-07-03 | 2024-01-22 | ブリストル－マイヤーズ スクイブ カンパニー | 組換えタンパク質を製造する方法 |
| CN113166695A (zh) | 2018-10-10 | 2021-07-23 | 勃林格殷格翰国际公司 | 用于高密度生物反应器培养中的膜气体转移的方法 |
| AR118536A1 (es) | 2019-04-01 | 2021-10-20 | Genentech Inc | Composiciones y métodos para estabilizar formulaciones que contienen proteína |
| WO2020210440A1 (en) | 2019-04-12 | 2020-10-15 | Geltor, Inc. | Recombinant elastin and production thereof |
| WO2021021973A1 (en) | 2019-08-01 | 2021-02-04 | Bristol-Myers Squibb Company | Methods of improving protein productivity in fed-batch cell cultures |
| EP4217383A1 (en) | 2020-09-22 | 2023-08-02 | Bristol-Myers Squibb Company | Methods for producing therapeutic proteins |
| US20250115666A1 (en) | 2021-08-05 | 2025-04-10 | Bristol-Myers Squibb Company | Cell culture methods for producing therapeutic proteins |
| US20240390869A1 (en) | 2021-09-21 | 2024-11-28 | Bristol-Myers Squibb Company | Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ236792A (en) * | 1990-01-19 | 1993-05-26 | Merck & Co Inc | Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions |
| US6096871A (en) * | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
-
1997
- 1997-10-20 DK DK97912841T patent/DK0941344T3/da active
- 1997-10-20 DE DE69729209T patent/DE69729209T2/de not_active Expired - Lifetime
- 1997-10-20 EP EP04004941A patent/EP1516629B1/en not_active Expired - Lifetime
- 1997-10-20 DK DK04004941.3T patent/DK1516629T3/da active
- 1997-10-20 CA CA2272842A patent/CA2272842C/en not_active Expired - Lifetime
- 1997-10-20 DE DE200412000047 patent/DE122004000047I1/de active Pending
- 1997-10-20 DE DE1997629209 patent/DE122004000047I2/de active Active
- 1997-10-20 AT AT97912841T patent/ATE267257T1/de active
- 1997-10-20 KR KR10-1999-7004671A patent/KR100532178B1/ko not_active Expired - Lifetime
- 1997-10-20 EP EP97912841A patent/EP0941344B1/en not_active Expired - Lifetime
- 1997-10-20 WO PCT/US1997/019041 patent/WO1998023761A1/en not_active Application Discontinuation
- 1997-10-20 PT PT97912841T patent/PT941344E/pt unknown
- 1997-10-20 IL IL13014397A patent/IL130143A0/xx active IP Right Grant
- 1997-10-20 ES ES97912841T patent/ES2221045T3/es not_active Expired - Lifetime
- 1997-10-20 AU AU49929/97A patent/AU731817C/en not_active Expired
- 1997-10-20 JP JP52464598A patent/JP3778945B2/ja not_active Expired - Lifetime
- 1997-10-27 ZA ZA979599A patent/ZA979599B/xx unknown
- 1997-11-04 AR ARP970105146A patent/AR008919A1/es active IP Right Grant
-
1999
- 1999-05-26 IL IL130143A patent/IL130143A/en not_active IP Right Cessation
-
2004
- 2004-11-10 LU LU91122C patent/LU91122I2/fr unknown
- 2004-11-12 NL NL300163C patent/NL300163I2/nl unknown
- 2004-12-10 FR FR04C0028C patent/FR04C0028I2/fr active Active
-
2005
- 2005-08-02 JP JP2005224609A patent/JP4309383B2/ja not_active Expired - Lifetime
-
2006
- 2006-05-11 IL IL175583A patent/IL175583A0/en not_active IP Right Cessation